Health Canada has launched a review of the increasingly popular pharmaceutical drug tramadol – a move that could prompt the department to reverse its controversial, decade-old decision not to classify the medication as an opioid. A change in the classification would put the drug on the same regulatory footing as opioids such as morphine, hydromorphone and oxycodone. It would also subject tramadol to tighter controls and enhanced reporting and record keeping.

Read More